![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bespak | LSE:BPK | London | Ordinary Share | GB0000946276 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 667.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:6952S Bespak PLC 14 October 2005 For immediate release 14 October 2005 Bespak plc Welcomes Positive Opinion on Exubera(R) Bespak plc (LSE: BPK), a leader in specialty medical devices, is pleased to note that Pfizer Inc announced yesterday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluations Agency (EMEA) has issued a positive opinion recommending the approval of Exubera(R) inhaleable insulin for the treatment of type 1 and type 2 diabetes in adults. The proposed therapeutic indication for Exubera(R) is for the treatment of adult patients with type 2 diabetes not adequately controlled with oral antidiabetic agents and requiring insulin therapy; and for the treatment of adult patients with type 1 diabetes, in addition to long or intermediate acting subcutaneous insulin, for whom the potential benefits of adding inhaled insulin outweigh the potential safety concerns. Exubera(R), which is the product of a joint-development program between Pfizer and sanofi-aventis, is an inhaled rapidly acting insulin that is inhaled into the lungs prior to eating, using a proprietary inhalation device and powdered insulin formulation developed by Nektar Therapeutics. The product represents a major advance in insulin delivery and will be the first non-injectable form of insulin available since the discovery of the drug in the 1920s. Bespak, in conjunction with Nektar, has developed the production process and will manufacture the proprietary inhalation device for Exubera(R). Exubera(R) was filed with the US Food & Drug Administration (FDA) on 2nd March 2005, and an FDA advisory committee recommended the approval of Exubera(R) on 8th September for the treatment of adults with type 1 and 2 diabetes. Pfizer awaits the approval by the FDA in the US as well as approval by the European Commission. It is anticipated that once fully launched, Exubera(R) will be a significant source of revenue growth for Bespak's Device & Manufacturing Services division. Mark Throdahl, Bespak's Chief Executive, said: "We are delighted by this recommendation from the CHMP, which moves us closer to European regulatory approval of this important new treatment for diabetes." For further information please call: Bespak plc Mark Throdahl - Chief Executive +44 (0) 20 1908 552 600 Martin Hopcroft - Group Finance Director Buchanan Communications +44 (0) 20 7466 5000 Tim Thompson / Mark Court / Mary-Jane Johnson Notes for Editors: About Bespak plc Bespak, a specialty medical devices company, is at the forefront of developing new delivery systems for the pharmaceutical industry. The company has a product range covering metered dose inhalers, dry powder devices, actuators and compliance aids. The company also develops and manufactures drug delivery devices for leading global pharmaceutical companies. The group, which has facilities in King's Lynn and Milton Keynes in the UK, is a public company quoted on the Official list of the London Stock Exchange (LSE: BPK). For more information, please visit www.bespak.com. About diabetes It is estimated that nearly 180 million people worldwide suffer from diabetes, and the number is expected to rise to 300 million people in the next 20 years. Currently, diabetes and its complications account for more than $100 billion in healthcare costs annually in the United States. This information is provided by RNS The company news service from the London Stock Exchange END RESILFSFIRLSLIE
1 Year Bespak Chart |
1 Month Bespak Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions